<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799431</url>
  </required_header>
  <id_info>
    <org_study_id>J2114</org_study_id>
    <secondary_id>IRB00270405</secondary_id>
    <nct_id>NCT04799431</nct_id>
  </id_info>
  <brief_title>Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer</brief_title>
  <official_title>A Pilot Study of a Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 study evaluating feasibility, safety, and immune response to a personalized&#xD;
      neoantigen vaccine combined with retifanlimab for MMR-p mCRC and mPDAC patients with&#xD;
      measurable disease following first-line FOLFIRINOX/FOLFOXIRI (FFX).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who receive at least one dose of personalized neoantigen vaccine</measure>
    <time_frame>9 months</time_frame>
    <description>Percentage of patients that receive at least one dose of personalized neoantigen vaccine in the maintenance setting among the total number of patients who achieved disease response (eligible for vaccine generation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing study drug-related toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants experiencing study drug-related adverse events Grade 3 or higher as defined by CTCAE v5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) per RECIST 1.1</measure>
    <time_frame>2 years</time_frame>
    <description>ORR is defined as the number of patients who are administered at least 1 dose of personalized neoantigen vaccine achieving a complete response (CR) or partial response (PR) based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) at any time during the study. CR = disappearance of all target lesions, PR is =&gt;30% decrease in sum of diameters of target lesions, progressive disease (PD) is &gt;20% increase in sum of diameters of target lesions, stable disease (SD) is &lt;30% decrease or &lt;20% increase in sum of diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) per iRECIST</measure>
    <time_frame>2 years</time_frame>
    <description>ORR is defined as the number of patients who are administered at least 1 dose of personalized neoantigen vaccine achieving a complete response (iCR) or partial response (iPR) based on the Response Evaluation Criteria in Solid Tumors (Immune-related RECIST (iRECIST) at any time during the study. iCR = disappearance of all target lesions, iPR is =&gt;30% decrease in sum of diameters of target lesions, progressive disease (iPD) is &gt;20% increase in sum of diameters of target lesions, stable disease (iSD) is &lt;30% decrease or &lt;20% increase in sum of diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>2 months</time_frame>
    <description>DCR is defined as the number of patients achieving a complete response (CR) or partial response (PR) and stable disease (SD) based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) at 2 months post first vaccination. CR = disappearance of all target lesions, PR is =&gt;30% decrease in sum of diameters of target lesions, progressive disease (PD) is &gt;20% increase in sum of diameters of target lesions, stable disease (SD) is &lt;30% decrease or &lt;20% increase in sum of diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>6 months</time_frame>
    <description>DCR is defined as the number of patients achieving a complete response (CR) or partial response (PR) and stable disease (SD) based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) at 6 months post first vaccination. CR = disappearance of all target lesions, PR is =&gt;30% decrease in sum of diameters of target lesions, progressive disease (PD) is &gt;20% increase in sum of diameters of target lesions, stable disease (SD) is &lt;30% decrease or &lt;20% increase in sum of diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>12 months</time_frame>
    <description>DCR is defined as the number of patients achieving a complete response (CR) or partial response (PR) and stable disease (SD) based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) at 12 months post first vaccination. CR = disappearance of all target lesions, PR is =&gt;30% decrease in sum of diameters of target lesions, progressive disease (PD) is &gt;20% increase in sum of diameters of target lesions, stable disease (SD) is &lt;30% decrease or &lt;20% increase in sum of diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) per RECIST 1.1</measure>
    <time_frame>4 years</time_frame>
    <description>PFS is defined as the number of months from the date of first personalized vaccine dose to disease progression (progressive disease [PD] or relapse from complete response [CR] as assessed using RECIST 1.1 criteria) or death due to any cause. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =&gt;30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is &gt;20% increase in sum of diameters of target lesions, Stable Disease (SD) is &lt;30% decrease or &lt;20% increase in sum of diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) per iRECIST</measure>
    <time_frame>4 years</time_frame>
    <description>PFS is defined as the number of months from the date of first personalized vaccine dose to disease progression (progressive disease [iPD] or relapse from complete response [iCR] as assessed using RECIST 1.1 criteria) or death due to any cause. Per iRECIST (iPFS) criteria, iCR = disappearance of all target lesions, Partial Response (iPR) is =&gt;30% decrease in sum of diameters of target lesions, Progressive Disease (iPD) is &gt;20% increase in sum of diameters of target lesions, Stable Disease (iSD) is &lt;30% decrease or &lt;20% increase in sum of diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>4 years</time_frame>
    <description>OS will be measured as the number of months from date of first personalized vaccine dose until death or end of follow-up (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Pancreatic Cancer Metastatic</condition>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Neoantigen Vaccine with Poly-ICLC adjuvant and Retifanlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants receive this intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoantigen Vaccine with Poly-ICLC adjuvant</intervention_name>
    <description>Neoantigen Vaccine with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22. 2 to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.&#xD;
Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC</description>
    <arm_group_label>Neoantigen Vaccine with Poly-ICLC adjuvant and Retifanlimab</arm_group_label>
    <other_name>Hiltonol® (Poly-ICLC)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retifanlimab</intervention_name>
    <description>500 mg will be administered as a 30 minute IV. Infusion (-5 min/+15min) on Day 1 of each 28 day cycle every 4 weeks.</description>
    <arm_group_label>Neoantigen Vaccine with Poly-ICLC adjuvant and Retifanlimab</arm_group_label>
    <other_name>INCMGA00012; MGA012</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years.&#xD;
&#xD;
          -  Have histologically or cytologically - proven cancer of the pancreas or colon.&#xD;
&#xD;
          -  Have tumor lesions amenable to repeated biopsy, and patient's acceptance to have a&#xD;
             tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be&#xD;
             biopsied with acceptable clinical risk (as judged by the investigator).&#xD;
&#xD;
          -  Measurable disease as per RECIST 1.1.&#xD;
&#xD;
          -  Have sufficient and accessible tissue for NGS and immune-phenotyping.&#xD;
&#xD;
          -  Have not received any prior systemic therapy in the metastatic setting for PDA or CRC.&#xD;
             Patients who have received adjuvant chemotherapy &gt;12 months prior to the diagnosis of&#xD;
             metastatic disease may be eligible.&#xD;
&#xD;
          -  ECOG performance status 0.&#xD;
&#xD;
          -  Life expectancy of greater than 6 months.&#xD;
&#xD;
          -  Patients must have adequate organ and marrow function defined by study-specified&#xD;
             laboratory tests prior to initial study drug.&#xD;
&#xD;
          -  Woman of childbearing potential must have a negative pregnancy test and follow&#xD;
             contraceptive guidelines as defined per protocol.&#xD;
&#xD;
          -  Men must use acceptable form of birth control while on study.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is a candidate for definitive surgical resection.&#xD;
&#xD;
          -  Is unwilling or unable to undergo standard of care therapy.&#xD;
&#xD;
          -  Known history or evidence of brain metastases and/or leptomeningeal spread.&#xD;
&#xD;
          -  Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1,&#xD;
             anti-PD-L2, anti-CTLA4, etc.).&#xD;
&#xD;
          -  Receiving active immunosuppressive agents or chronic use of systemic corticosteroids&#xD;
             within 14 days of vaccine treatment.&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in the past 5&#xD;
             years, or a documented history of clinically severe autoimmune disease, or a syndrome&#xD;
             that requires systemic steroids or immunosuppressive agents.&#xD;
&#xD;
          -  Known history or concurrent interstitial lung disease.&#xD;
&#xD;
          -  Has a pulse oximetry &lt; 95% on room air.&#xD;
&#xD;
          -  Requires the use of home oxygen.&#xD;
&#xD;
          -  Infection with HIV or hepatitis B or C.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, uncontrolled&#xD;
             infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia,&#xD;
             metastatic cancer, or psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements.&#xD;
&#xD;
          -  Has been diagnosed with another cancer or myeloproliferative disorder within the past&#xD;
             5 year.&#xD;
&#xD;
          -  Has had surgery within 28 days of dosing of investigational agent, excluding minor&#xD;
             procedures (dental work, skin biopsy, etc.), celiac plexus block, and biliary stent&#xD;
             placement.&#xD;
&#xD;
          -  Has received any non-oncology live vaccine therapy used for prevention of infectious&#xD;
             diseases within 28 days of study treatment.&#xD;
&#xD;
          -  If at the time of signing informed consent, a regular user (including &quot;recreational&#xD;
             use&quot;) of any illicit drugs or other substance abuse (including alcohol) that could&#xD;
             potentially interfere with adherence to study procedures or requirements.&#xD;
&#xD;
          -  Any other sound medical, psychiatric, and/or social reason as determined by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Unwilling or unable to follow the study schedule for any reason.&#xD;
&#xD;
          -  Are pregnant or breastfeeding.&#xD;
&#xD;
          -  Any radiological or clinical pleural effusions or ascites.&#xD;
&#xD;
          -  Any peritoneal involvement by the tumor.&#xD;
&#xD;
          -  History of malignant small bowel obstruction.&#xD;
&#xD;
          -  On parenteral nutrition.&#xD;
&#xD;
          -  Any liver metastasis greater than 3 cm or greater than 5 liver metastases.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to Hiltonol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nilofer Azad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SKCCC at the Johns Hopkins Medical Institution</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trish Brothers, RN</last_name>
    <phone>410-614-3644</phone>
    <email>GIClinicalTrials@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joann Santmyer, RN</last_name>
    <phone>(410) 583-2970</phone>
    <email>GIClinicalTrials@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Trish Brothers, RN</last_name>
      <phone>410-614-3644</phone>
      <email>GIClinicalTrials@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joann Santmyer, RN</last_name>
      <phone>410-583-2970</phone>
      <email>GIClinicalTrials@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoantigen Vaccines</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>Retifanlimab</keyword>
  <keyword>Cancer Vaccines</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Metastatic colon cancer</keyword>
  <keyword>Pancreatic Ductal Adenocarcinoma (PDAC)</keyword>
  <keyword>Metastatic pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poly I-C</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
    <mesh_term>Poly ICLC</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

